Please ensure Javascript is enabled for purposes of website accessibility

Why Spectrum Pharmaceuticals, Inc. Is Up Big Today

By Brian Feroldi - May 17, 2018 at 1:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jumped after the company shared new details from an important phase 3 study. Here's what investors need to know.

What happened

In response to the company sharing more details of a phase 3 study with investors, shares of Spectrum Pharmaceuticals (SPPI 5.31%), a small-cap biotech focused on hematology and oncology, jumped 16% as of 12:40 p.m. EDT on Thursday.

So what

The study in question is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum's drug Rolontis when compared to Amgen's (AMGN -0.92%) megablockbuster drug Neulasta in patients with early-stage breast cancer.

While the company had already announced in February that the trial had met its primary endpoint, the initial release was light on details. Spectrum's new release today confirmed that all secondary endpoints of the study were met and that adverse events between the two drugs were similar. 

Doctor giving double thumbs up

Image source: Getty Images.

Here's what Spectrum's CEO Joe Turgeon had to say about the release of this additional data,"We are pleased that ROLONTIS has shown strong non-inferiority data and comparable safety profile to the current standard of care. ROLONTIS has the potential to be the first novel drug in this multibillion dollar market in more than 15 years."

Given the additional insight, it isn't hard to figure out why traders are bidding up shares of this red-hot stock yet again.

Now what

Spectrum has a second phase 3 trial under way that is studying Rolontis. The trial is expected to be completed before the end of the year, and management reaffirmed that it is on track to submit the drug for review in the fourth quarter of 2018. Since all of the updates we've seen thus far with Rolontis have been positive, the odds look good that Spectrum has another winner on its hands. If true, it wouldn't surprise this Fool one bit to see Spectrum's incredible run continue from here.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Spectrum Pharmaceuticals, Inc. Stock Quote
Spectrum Pharmaceuticals, Inc.
$0.81 (5.31%) $0.04
Amgen Inc. Stock Quote
Amgen Inc.
$243.28 (-0.92%) $-2.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.